$0.38
-0.04 (-8.59%)
Open$0.41
Previous Close$0.42
Day High$0.45
Day Low$0.35
52W High$1.50
52W Low$0.37
Volume—
Avg Volume341.1K
Market Cap6.75M
P/E Ratio—
EPS$-0.91
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,584.2% upside
Current
$0.38
$0.38
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.23M | 7.84M | 3.80M |
| Net Income | -16,968,001 | -11,698,483 | 985.2K |
| Profit Margin | -800.8% | -760.7% | 25.9% |
| EBITDA | -25,833,057 | -18,799,911 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +30.5% | +30.5% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |